Press

2023-11-17

Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the third quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 9,2 million (SEK 8,7 million). Operating income for the third quarter amounted to SEK...

Read More
2022-10-27

Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

This is a translation of the interim report published in Swedish at October 26, 2022

Read More
2021-11-19

Interim report for third quarter 2021,1 January – 30 September 2021 Kancera AB (publ.), org.nr. 556806-8851

The year in brief Juli – SeptemberFinancial summary of the third quarter Net sales amounted to SEK 0 million (0,05 million). R&D costs amounted to SEK 10,9 million (8,8 million). Operating profit for the third quarter amounted to SEK...

Read More
2020-11-20

Interim report for the third quarter 2020, January 1st – September 30th, 2020

Third quarter in brief as well as the period 1 January – 30 September 2020 Net sales for the period (January to September) amounted to SEK 0,09 million (3,3 million), of which the third quarter contributed SEK 0,05 million...

Read More
2019-11-26

Interim report for the third quarter 2019, 1 January – 30 September 2019

Third quarter in brief 1 July – 30 September 2019 Net sales for the period (January to September) amounted to SEK 3,3 Million (0,1 Million) of which the third quarter contributed SEK 0,2 Million (0,0 Million). R&D costs for...

Read More
2018-11-23

INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 30th September 2018

PERIOD JAN – SEPTEMBER 2018, AND THIRD QUARTER IN BRIEF • Net sales for the period (January to September) amounted to SEK 0.1 million (SEK 0.1 million) of which the third quarter amounted to SEK 0.1 million (SEK 0.0 million). • R&D...

Read More
2017-11-17

INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 30th September 2017

PERIOD 1 JAN – 30 SEPT 2017 IN BRIEF • R&D expenses for the period amounted to SEK 39.8 million (13.3 million ), of which the third quarter amounted to SEK 14.7 million (4.6 million ) • Operating profit for the period amounted to...

Read More
2016-11-18

Interim Report for Kancera AB (publ) Q3 2016, January 1 – September 30, 2016

The period January to September 2016 in brief  R&D expenses for the period amounted to SEK 13.3m (SEK 12.1m) of which the third quarter constituted SEK 4.6m (SEK 3.2m).  Operating income for the period amounted to SEK -15.8m (SEK...

Read More
2015-11-20

Interim Report for Kancera AB (publ) Q3 2015. January 1 – September 30, 2015.

The period January to September 2015 and the third quarter 2015 in brief R&D expenses for the period amounted to SEK 12.1m (SEK 9.6m) of which the third quarter constituted SEK 3.2m (SEK 2.7m). Operating income for the period...

Read More
2014-11-21

Interim Report for Kancera AB (publ) Q3 2014

January 1 - September 30, 2014. All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. In connection with this Kancera...

Read More